Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| (17 intermediate revisions by 3 users not shown) | |||
| Line 7: | Line 7: | ||
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | ||
| + | :* Conformance Checklists (refer to Appendix C in the Profile document - pg 42) | ||
| + | :* Assessment Procedures (refer to Section 4 in the Profile document - pg 30) | ||
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | ||
| − | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 | + | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] |
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | * [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | + | * [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-2.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] |
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]] | *[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]] | ||
| − | *[[Media:MRE- | + | *[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]] |
| − | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]] | + | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1, 2017-06-26]] |
| + | |||
| + | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | ||
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
| Line 30: | Line 34: | ||
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | '''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | ||
| + | *[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] (<font color=green>'''Public Comment Open'''</font>: November 1, 2019 - January 10, 2020) | ||
| + | |||
| + | *[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21]] (<font color=green>'''Public Comment Open'''</font>: October 21 - December 18, 2019) | ||
| + | :*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: QIBA US SWS Checklists for Implementation of the SWS Profile, 2019-10-21]] (<font color=green>'''Public Comment Open'''</font>: October 21 - December 18, 2019) | ||
| − | *[[Media: | + | *[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019) |
| − | :*[[Media:QIBA CT Lung Density Protocols-Appendix D.xlsx|QIBA CT Lung Density Protocols-Appendix D, 2019-06-26]] ( | + | :*[[Media:QIBA CT Lung Density Protocols-Appendix D.xlsx|QIBA CT Lung Density Protocols-Appendix D, 2019-06-26]] ('''closed''' on October 16, 2019) |
| − | *[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] ('''closed''' on | + | *[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] ('''closed''' on April 5th, 2019) |
| − | *[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] ('''closed''' on | + | *[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] ('''closed''' on June 3rd, 2019) |
Revision as of 20:50, 1 November 2019
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
- Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
- Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Please submit comments using the online form
- SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21 (Public Comment Open: November 1, 2019 - January 10, 2020)
- QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21 (Public Comment Open: October 21 - December 18, 2019)
- Appendix E: QIBA US SWS Checklists for Implementation of the SWS Profile, 2019-10-21 (Public Comment Open: October 21 - December 18, 2019)
- QIBA CT Lung Density Profile 2019-09-03 (Contains Conformance Checklist, Appendix B) (closed on October 16, 2019)
- QIBA CT Lung Density Protocols-Appendix D, 2019-06-26 (closed on October 16, 2019)
- Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05 (closed on April 5th, 2019)
- Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26 (closed on June 3rd, 2019)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations .
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL
Example:
- QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)